Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
SI-Bone price target lowered to $24 from $28 at Needham » 09:16
08/09/22
08/09
09:16
08/09/22
09:16
SIBN

SI-Bone

$16.52 /

-0.21 (-1.26%)

Needham analyst David…

Needham analyst David Saxon lowered the firm's price target on SI-Bone to $24 from $28 and keeps a Buy rating on the shares. The company's Q2 results were "solid" as its procedure volume growth of 23% marked record high levels in June, but its gross margins of 86.5% were down 280 basis points due to higher cost of operations, the analyst tells investors in a research note.

ShowHide Related Items >><<
SIBN SI-Bone
$16.52 /

-0.21 (-1.26%)

SIBN SI-Bone
$16.52 /

-0.21 (-1.26%)

05/10/22 Canaccord
SI-Bone price target lowered to $25 from $32 at Canaccord
04/07/22 Cantor Fitzgerald
SI-Bone assumed with an Overweight at Cantor Fitzgerald
12/21/21 Truist
SI-Bone price target lowered to $30 from $35 at Truist
11/09/21 Needham
SI-Bone price target lowered to $32 from $37 at Needham
SIBN SI-Bone
$16.52 /

-0.21 (-1.26%)

Earnings
SI-Bone backs FY22 revenue view $106M-$108M, consensus $107.26M » 16:28
08/08/22
08/08
16:28
08/08/22
16:28
SIBN

SI-Bone

$16.52 /

-0.21 (-1.26%)

The company said,…

The company said, "The Company continues to expect total 2022 revenue of approximately $106 million to $108 million, representing growth of 18% to 20% compared to full year 2021."

ShowHide Related Items >><<
SIBN SI-Bone
$16.52 /

-0.21 (-1.26%)

SIBN SI-Bone
$16.52 /

-0.21 (-1.26%)

05/10/22 Canaccord
SI-Bone price target lowered to $25 from $32 at Canaccord
04/07/22 Cantor Fitzgerald
SI-Bone assumed with an Overweight at Cantor Fitzgerald
12/21/21 Truist
SI-Bone price target lowered to $30 from $35 at Truist
11/09/21 Needham
SI-Bone price target lowered to $32 from $37 at Needham
SIBN SI-Bone
$16.52 /

-0.21 (-1.26%)

Earnings
SI-Bone reports Q2 EPS (54c) vs. (42c) last year » 16:27
08/08/22
08/08
16:27
08/08/22
16:27
SIBN

SI-Bone

$16.52 /

-0.21 (-1.26%)

Reports Q2 revenue…

Reports Q2 revenue $25.59M, consensus $25.17M. "I am pleased with the accelerating growth in the U.S. which allowed us to deliver record revenue in the quarter with iFuse-3D and iFuse-TORQ as the two best products on the market for MIS SI joint fusion," said Laura Francis, CEO of SI-BONE. "The recent launch of iFuse Bedrock Granite and the expanded trauma indication for iFuse-TORQ will complement our core market growth as we support our surgeons in improving patient outcomes across modalities. With the best-in-class portfolio of sacropelvic solutions, an industry-leading commercial infrastructure and a strong cash position, we have the organizational resources to capitalize on the healthy demand dynamics and deliver accelerating top line growth."

ShowHide Related Items >><<
SIBN SI-Bone
$16.52 /

-0.21 (-1.26%)

SIBN SI-Bone
$16.52 /

-0.21 (-1.26%)

05/10/22 Canaccord
SI-Bone price target lowered to $25 from $32 at Canaccord
04/07/22 Cantor Fitzgerald
SI-Bone assumed with an Overweight at Cantor Fitzgerald
12/21/21 Truist
SI-Bone price target lowered to $30 from $35 at Truist
11/09/21 Needham
SI-Bone price target lowered to $32 from $37 at Needham
SIBN SI-Bone
$16.52 /

-0.21 (-1.26%)

Over a quarter ago
Hot Stocks
SI-Bone announces FDA clearance for expanded indication of iFuse-TORQ system » 08:04
06/13/22
06/13
08:04
06/13/22
08:04
SIBN

SI-Bone

$14.43 /

-0.07 (-0.48%)

SI-BONE announced an FDA…

SI-BONE announced an FDA clearance for iFuse-TORQ for pelvic fracture fixation, including acute, non-acute and non-traumatic fractures. Fractures covered in this clearance include pelvic fragility fractures and pelvic insufficiency fractures. Together, these constitute an approximately $300M market opportunity. Sacral fragility and insufficiency fractures are common and often devastating for patients and healthcare systems, where: 120,000 sacral fragility or insufficiency fractures occur annually in the US; 78% of patients are treated with bedrest leading to 14- to 45-day hospital stays; 27% 1-year mortality results from bedrest-associated complications. "Since its launch in 2021, iFuse-TORQ has been used to treat many patients suffering from a pelvic fracture or sacroiliac joint dysfunction," said Laura Francis, CEO of SI-BONE. "This pelvic fracture fixation indication expansion comes on the coattails of the iFuse Bedrock Granite launch and expands SI-BONE's position as the market leader in the sacropelvic space."

ShowHide Related Items >><<
SIBN SI-Bone
$14.43 /

-0.07 (-0.48%)

SIBN SI-Bone
$14.43 /

-0.07 (-0.48%)

05/10/22 Canaccord
SI-Bone price target lowered to $25 from $32 at Canaccord
04/07/22 Cantor Fitzgerald
SI-Bone assumed with an Overweight at Cantor Fitzgerald
12/21/21 Truist
SI-Bone price target lowered to $30 from $35 at Truist
11/09/21 Needham
SI-Bone price target lowered to $32 from $37 at Needham
SIBN SI-Bone
$14.43 /

-0.07 (-0.48%)

Hot Stocks
SI-Bone receives FDA 510(k) clearance for iFuse Bedrock Granite » 08:13
05/31/22
05/31
08:13
05/31/22
08:13
SIBN

SI-Bone

$14.37 /

+0.195 (+1.38%)

SI-BONE announces FDA…

SI-BONE announces FDA 510(k) premarket clearance of the iFuse Bedrock Granite Implant System. The Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. This clearance follows the earlier designation by the Food & Drug Administration, FDA, of Granite as a Breakthrough Device, BDD, and most recently, a proposal by the Centers for Medicare and Medicaid Services, CMS, for a New Technology Add-on Payment, NTAP. CMS has also issued new technology "Section X" ICD-10 unique procedure coding for hospitals to report NTAP eligible cases that use Granite as an Internal Fixation Device with Tulip Connector, for either open or percutaneous sacroiliac joint fusion and sacropelvic fixation. "We are thrilled to receive FDA 510(k) clearance to launch Granite to the market. The anticipation has been building ever since the FDA awarded BDD for its promise of providing more effective treatment than the current standard of care, and CMS' recently proposed NTAP, recognizing it as a new technology that can provide substantial clinical improvement over already available therapies," said Laura Francis, CEO of SI-BONE. "Based on the early pre-clinical data from in vivo animal studies suggesting significant bone ingrowth and superior mechanical stability, internal studies showing markedly improved biomechanics, and initial feedback from surgeons, we couldn't be more enthusiastic about Granite's clinical and commercial promise as a uniquely disruptive technology."

ShowHide Related Items >><<
SIBN SI-Bone
$14.37 /

+0.195 (+1.38%)

SIBN SI-Bone
$14.37 /

+0.195 (+1.38%)

05/10/22 Canaccord
SI-Bone price target lowered to $25 from $32 at Canaccord
04/07/22 Cantor Fitzgerald
SI-Bone assumed with an Overweight at Cantor Fitzgerald
12/21/21 Truist
SI-Bone price target lowered to $30 from $35 at Truist
11/09/21 Needham
SI-Bone price target lowered to $32 from $37 at Needham
SIBN SI-Bone
$14.37 /

+0.195 (+1.38%)

Recommendations
SI-Bone price target lowered to $25 from $32 at Canaccord » 07:57
05/10/22
05/10
07:57
05/10/22
07:57
SIBN

SI-Bone

$15.10 /

-2.175 (-12.59%)

Canaccord analyst Kyle…

Canaccord analyst Kyle Rose lowered the firm's price target on SI-Bone to $25 from $32 and keeps a Buy rating on the shares. The analyst said if shares continue to sell off, he suggests investors take a hard look at the company ahead of what he thinks can be a prolonged period of execution in 2022 as investments in the commercial infrastructure translate to productivity gains and upside to estimates.

ShowHide Related Items >><<
SIBN SI-Bone
$15.10 /

-2.175 (-12.59%)

SIBN SI-Bone
$15.10 /

-2.175 (-12.59%)

04/07/22 Cantor Fitzgerald
SI-Bone assumed with an Overweight at Cantor Fitzgerald
12/21/21 Truist
SI-Bone price target lowered to $30 from $35 at Truist
11/09/21 Needham
SI-Bone price target lowered to $32 from $37 at Needham
09/30/21 Truist
SI-Bone price target lowered to $37 from $43 at Truist
SIBN SI-Bone
$15.10 /

-2.175 (-12.59%)

Earnings
SI-Bone backs prior FY22 revenue view $106M-$108M, consensus $107.35M  16:23
05/09/22
05/09
16:23
05/09/22
16:23
SIBN

SI-Bone

$15.10 /

-2.175 (-12.59%)

 
ShowHide Related Items >><<
SIBN SI-Bone
$15.10 /

-2.175 (-12.59%)

SIBN SI-Bone
$15.10 /

-2.175 (-12.59%)

04/07/22 Cantor Fitzgerald
SI-Bone assumed with an Overweight at Cantor Fitzgerald
12/21/21 Truist
SI-Bone price target lowered to $30 from $35 at Truist
11/09/21 Needham
SI-Bone price target lowered to $32 from $37 at Needham
09/30/21 Truist
SI-Bone price target lowered to $37 from $43 at Truist
SIBN SI-Bone
$15.10 /

-2.175 (-12.59%)

Earnings
SI-Bone reports Q1 EPS (52), consensus (43c) » 16:22
05/09/22
05/09
16:22
05/09/22
16:22
SIBN

SI-Bone

$15.10 /

-2.175 (-12.59%)

Reports Q1 revenue…

Reports Q1 revenue $22.4M, consensus $21.87M.

ShowHide Related Items >><<
SIBN SI-Bone
$15.10 /

-2.175 (-12.59%)

SIBN SI-Bone
$15.10 /

-2.175 (-12.59%)

04/07/22 Cantor Fitzgerald
SI-Bone assumed with an Overweight at Cantor Fitzgerald
12/21/21 Truist
SI-Bone price target lowered to $30 from $35 at Truist
11/09/21 Needham
SI-Bone price target lowered to $32 from $37 at Needham
09/30/21 Truist
SI-Bone price target lowered to $37 from $43 at Truist
SIBN SI-Bone
$15.10 /

-2.175 (-12.59%)

Hot Stocks
SI-Bone announces NTAP for adult spinal deformity treatment » 08:05
04/19/22
04/19
08:05
04/19/22
08:05
SIBN

SI-Bone

$19.81 /

-1.305 (-6.18%)

SI-Bone announced that…

SI-Bone announced that the Centers for Medicare and Medicaid Services, CMS, has proposed a New Technology Add-on Payment, NTAP, for the iFuse Bedrock Granite implant. The Granite implant is intended to provide sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. The Granite implant was awarded Breakthrough Device Designation by the FDA and is anticipated to receive regulatory clearance this year. "We are pleased CMS recognizes iFuse Bedrock Granite, a Breakthrough Device, as being the sacroiliac joint fixation and fusion technology to treat adult spinal deformity that potentially will allow hospitals to receive incremental reimbursement through the NTAP program," said Laura Francis, CEO of SI-BONE. "Once finalized, the NTAP will help ensure that Medicare patients have access to this innovative technology."

ShowHide Related Items >><<
SIBN SI-Bone
$19.81 /

-1.305 (-6.18%)

04/07/22 Cantor Fitzgerald
SI-Bone assumed with an Overweight at Cantor Fitzgerald
12/21/21 Truist
SI-Bone price target lowered to $30 from $35 at Truist
11/09/21 Needham
SI-Bone price target lowered to $32 from $37 at Needham
09/30/21 Truist
SI-Bone price target lowered to $37 from $43 at Truist
SIBN SI-Bone
$19.81 /

-1.305 (-6.18%)

Initiation
SI-Bone assumed with an Overweight at Cantor Fitzgerald » 07:05
04/07/22
04/07
07:05
04/07/22
07:05
SIBN

SI-Bone

$21.24 /

-0.09 (-0.42%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Ross Osborn assumed coverage of SI-Bone with an Overweight rating and $34 price target. Osborn continues believe SI-Bone is capable of growing revenue by 20%+ p.a. longer-term in a normal operating environment and believes adoption of its iFuse procedure will accelerate in CY22 as COVID-related headwinds subside and the company benefits from a higher physician fee, improved sales force productivity, positive five-year data, and broader insurance coverage, the analyst tells investors in a research note. He views the company's shares as materially undervalued relative to small-cap high-growth MedTech peers.

ShowHide Related Items >><<
SIBN SI-Bone
$21.24 /

-0.09 (-0.42%)

SIBN SI-Bone
$21.24 /

-0.09 (-0.42%)

12/21/21 Truist
SI-Bone price target lowered to $30 from $35 at Truist
11/09/21 Needham
SI-Bone price target lowered to $32 from $37 at Needham
09/30/21 Truist
SI-Bone price target lowered to $37 from $43 at Truist
06/08/21
Fly Intel: Top five analyst initiations
SIBN SI-Bone
$21.24 /

-0.09 (-0.42%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.